UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): February 15, 2005
__________
SIGA Technologies, Inc.
-----------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 0-23047 13-3864870
-------- ------- ----------
(State or other Jurisdiction of (Commission File (I.R.S. Employer
Incorporation or Organization) Number) Identification Number)
420 Lexington Avenue, Suite 601, New York, New York 10170
--------------------------------------------------- ---------
(Address of Principal Executive Offices) (Zip Code)
(212) 672-9100
--------------
(Registrant's telephone number, including area code)
ITEM 8.01. Other Events.
On February 15, 2005, SIGA Technologies, Inc., a Delaware corporation,
issued a press release pursuant to which it announced that SIGA and TransTech
Pharma, Inc., a privately held Delaware corporation, received a $2.7 million
challenge grant from the National Institutes of Health to support the
development of protease inhibitors to treat orthopoxvirus infections, such as
smallpox and monkeypox. The grant award will be used to fund SIGA and TransTech
Pharma's joint research efforts directed toward the discovery, optimization, and
advancement of lead drug candidates for smallpox and biowarfare defense. A copy
of the press release is attached hereto as Exhibit 99.1, which is incorporated
in this Item 8.01 by reference.
ITEM 9. Financial Statements and Exhibits
---------------------------------
(c) Exhibits
Exhibit No. Description
----------- -----------
99.1 Press Release dated February 15, 2005.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
SIGA TECHNOLOGIES, INC.
By: /s/ Thomas N. Konatich
--------------------------
Thomas N. Konatich
Chief Financial Officer
Date: February 15, 2005
3
EXHIBIT INDEX
-------------
Exhibit Number Description
-------------- -----------
99.1 Press Release dated February 15, 2005
4